Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)
Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Royalty Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was $2.98B, up 23.7% year over year. For fiscal 2025 it was $2.49B, down 10.1% from the year before. The highest annual figure on record is $2.99B in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49B | -10.1% |
| FY2024 | Dec 31, 2024 | $2.77B | -7.3% |
| FY2023 | Dec 31, 2023 | $2.99B | +39.4% |
| FY2022 | Dec 31, 2022 | $2.14B | +6.3% |
| FY2021 | Dec 31, 2021 | $2.02B | -0.8% |
| FY2020 | Dec 31, 2020 | $2.03B | +22.0% |
| FY2019 | Dec 31, 2019 | $1.67B | +3.0% |
| FY2018 | Dec 31, 2018 | $1.62B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $728.46M | +100.1% |
| Q1 FY2026 | Mar 31, 2026 | $718.23M | +20.5% |
| Q4 FY2025 | Dec 31, 2025 | $827.15M | +11.4% |
| Q3 FY2025 | Sep 30, 2025 | $702.62M | -0.1% |
| Q2 FY2025 | Jun 30, 2025 | $363.98M | -44.7% |
| Q1 FY2025 | Mar 31, 2025 | $596.08M | -10.3% |
| Q4 FY2024 | Dec 31, 2024 | $742.53M | -3.9% |
| Q3 FY2024 | Sep 30, 2024 | $703.61M | +22.7% |
| Q2 FY2024 | Jun 30, 2024 | $658.21M | +8.3% |
| Q1 FY2024 | Mar 31, 2024 | $664.64M | -35.7% |
| Q4 FY2023 | Dec 31, 2023 | $772.63M | +35.6% |
| Q3 FY2023 | Sep 30, 2023 | $573.52M | +6.4% |
| Q2 FY2023 | Jun 30, 2023 | $607.82M | +5.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.03B | +124.6% |
| Q4 FY2022 | Dec 31, 2022 | $569.93M | +16.3% |
| Q3 FY2022 | Sep 30, 2022 | $538.83M | +14.7% |
| Q2 FY2022 | Jun 30, 2022 | $574.95M | +8.1% |
| Q1 FY2022 | Mar 31, 2022 | $460.27M | -12.5% |
| Q4 FY2021 | Dec 31, 2021 | $489.96M | -13.4% |
| Q3 FY2021 | Sep 30, 2021 | $469.76M | -7.7% |
| Q2 FY2021 | Jun 30, 2021 | $531.72M | +8.7% |
| Q1 FY2021 | Mar 31, 2021 | $526.10M | +11.7% |
| Q4 FY2020 | Dec 31, 2020 | $565.67M | +18.2% |
| Q3 FY2020 | Sep 30, 2020 | $508.85M | +21.4% |
| Q2 FY2020 | Jun 30, 2020 | $489.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $471.10M | – |
| Q4 FY2019 | Dec 31, 2019 | $478.43M | – |
| Q3 FY2019 | Sep 30, 2019 | $419.03M | – |
See a number that looks wrong?